Shaoli Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shaoli Li has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jianbo Lai
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications Lixia Huang
Department of Respiratory Medicine, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
2 shared publications- Shaohua Hu
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Yanbin Zhou
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University
2 shared publications - Baomo Liu
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
1 shared publication Bing Liu
Novogene Bioinformatics Institute, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 15 March 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , 1-26
Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis
We employed a Bayesian network meta-analysis for comparison of the efficacy and tolerability of US Food and Drug Administration (FDA)-approved atypical antipsychotics (AAPs) for the treatment of bipolar patients with depressive episodes. Sixteen randomized controlled trials with 7234 patients treated by one of the five AAPs (cariprazine, lumateperone, lurasidone, olanzapine, and quetiapine) were included. For the response rate (defined as an improvement of ≥50% from baseline on the Montgomery-Åsberg Depression Rating Scale [MADRS]), all AAPs were more efficacious than placebo. For the remission rate (defined as the endpoint of MADRS ≤12 or ≤ 10), cariprazine, lurasidone, olanzapine, and quetiapine had higher remission rates than placebo. In terms of tolerability, olanzapine was unexpectedly associated with lower odds of all-cause discontinuation in comparison with placebo, whereas quetiapine was associated with higher odds of discontinuation due to adverse events than placebo. Compared with placebo, lumateperone, olanzapine, and quetiapine showed higher odds of somnolence. Lumateperone had a lower rate of ≥ weight gain of 7% than placebo and other treatments. Olanzapine was associated with a significant increase from baseline in total cholesterol and triglycerides than placebo. These findings inform individualized prescriptions of AAPs for treating bipolar depression in clinical practice.
- 15 March 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , 1-26
Open AccessEfficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis
We employed a Bayesian network meta-analysis for comparison of the efficacy and tolerability of US Food and Drug Administration (FDA)-approved atypical antipsychotics (AAPs) for the treatment of bipolar patients with depressive episodes. Sixteen randomized controlled trials with 7234 patients treated by one of the five AAPs (cariprazine, lumateperone, lurasidone, olanzapine, and quetiapine) were included. For the response rate (defined as an improvement of ≥50% from baseline on the Montgomery-Åsberg Depression Rating Scale [MADRS]), all AAPs were more efficacious than placebo. For the remission rate (defined as the endpoint of MADRS ≤12 or ≤ 10), cariprazine, lurasidone, olanzapine, and quetiapine had higher remission rates than placebo. In terms of tolerability, olanzapine was unexpectedly associated with lower odds of all-cause discontinuation in comparison with placebo, whereas quetiapine was associated with higher odds of discontinuation due to adverse events than placebo. Compared with placebo, lumateperone, olanzapine, and quetiapine showed higher odds of somnolence. Lumateperone had a lower rate of ≥ weight gain of 7% than placebo and other treatments. Olanzapine was associated with a significant increase from baseline in total cholesterol and triglycerides than placebo. These findings inform individualized prescriptions of AAPs for treating bipolar depression in clinical practice.
- Open Access
- 25 July 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (2)
Circulating T‐cell subsets discrepancy between bipolar disorder and major depressive disorder during mood episodes: A naturalistic, retrospective study of 1015 cases
Aims: We aimed to investigate whether peripheral T‐cell subsets could be a biomarker to distinguish major depressive disorder (MDD) and bipolar disorder (BD). Methods: Medical records of hospitalized patients in the Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, from January 2015 to September 2020 with a discharge diagnosis of MDD or BD were reviewed. Patients who underwent peripheral blood examination of T‐cell subtype proportions, including CD3+, CD4+, CD8+ T‐cell, and natural killer (NK) cells, were enrolled. The Chi‐square test, t ‐test, or one‐way analysis of variance were used to analyze group differences. Demographic profiles and T‐cell data were used to construct a random forest classifier‐based diagnostic model. Results: Totally, 98 cases of BD mania, 459 cases of BD depression (BD‐D), and 458 cases of MDD were included. There were significant differences in the proportions of CD3+, CD4+, CD8+ T‐cell, and NK cells among the three groups. Compared with MDD, the BD‐D group showed higher CD8+ but lower CD4+ T‐cell and a significantly lower ratio of CD4+ and CD8+ proportions. The random forest model achieved an area under the curve of 0.77 (95% confidence interval: 0.71–0.83) to distinguish BD‐D from MDD patients. Conclusion: These findings imply that BD and MDD patients may harbor different T‐cell inflammatory patterns, which could be a potential diagnostic biomarker for mood disorders.
- 25 July 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (2)
Open AccessCirculating T‐cell subsets discrepancy between bipolar disorder and major depressive disorder during mood episodes: A naturalistic, retrospective study of 1015 cases
Aims: We aimed to investigate whether peripheral T‐cell subsets could be a biomarker to distinguish major depressive disorder (MDD) and bipolar disorder (BD). Methods: Medical records of hospitalized patients in the Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, from January 2015 to September 2020 with a discharge diagnosis of MDD or BD were reviewed. Patients who underwent peripheral blood examination of T‐cell subtype proportions, including CD3+, CD4+, CD8+ T‐cell, and natural killer (NK) cells, were enrolled. The Chi‐square test, t ‐test, or one‐way analysis of variance were used to analyze group differences. Demographic profiles and T‐cell data were used to construct a random forest classifier‐based diagnostic model. Results: Totally, 98 cases of BD mania, 459 cases of BD depression (BD‐D), and 458 cases of MDD were included. There were significant differences in the proportions of CD3+, CD4+, CD8+ T‐cell, and NK cells among the three groups. Compared with MDD, the BD‐D group showed higher CD8+ but lower CD4+ T‐cell and a significantly lower ratio of CD4+ and CD8+ proportions. The random forest model achieved an area under the curve of 0.77 (95% confidence interval: 0.71–0.83) to distinguish BD‐D from MDD patients. Conclusion: These findings imply that BD and MDD patients may harbor different T‐cell inflammatory patterns, which could be a potential diagnostic biomarker for mood disorders.
- 21 December 2021
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 42 (2) , 219-221
Mania in a Patient With Pituitrin-Associated Hyponatremia
An abstract is unavailable. This article is available as a PDF only.
- 21 December 2021
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 42 (2) , 219-221
Mania in a Patient With Pituitrin-Associated Hyponatremia
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 January 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (1) , 212-218
In vitro effects of N-acetylcysteine alone and combined with tigecycline on planktonic cells and biofilms of Acinetobacter baumannii
In vitro effects of N-acetylcysteine alone and combined with tigecycline on planktonic cells and biofilms of Acinetobacter baumannii
- 1 January 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (1) , 212-218
Open AccessIn vitro effects of N-acetylcysteine alone and combined with tigecycline on planktonic cells and biofilms of Acinetobacter baumannii
In vitro effects of N-acetylcysteine alone and combined with tigecycline on planktonic cells and biofilms of Acinetobacter baumannii
- Open Access
- 29 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (40) , 67810-67820
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study
- 29 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (40) , 67810-67820
Open AccessEvaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study